Ballwin, MO, United States of America

Matthew J Pelc

USPTO Granted Patents = 3 

Average Co-Inventor Count = 12.0

ph-index = 3

Forward Citations = 44(Granted Patents)


Company Filing History:


Years Active: 2009-2011

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Matthew J Pelc

Introduction

Matthew J Pelc is an accomplished inventor based in Ballwin, MO (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that address various diseases and conditions. With a total of 3 patents to his name, Pelc's work is recognized for its potential impact on healthcare.

Latest Patents

Pelc's latest patents include innovative compounds that are useful in treating diseases such as asthma. One of his notable inventions is related to heterocyclic compounds, which are described as compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof. These compounds are designed to provide therapeutic benefits for various conditions. Another significant patent involves nicotinamide derivatives, which also focus on treating diseases like asthma through similar chemical formulations.

Career Highlights

Matthew J Pelc is currently associated with Pfizer Corporation, a leading global pharmaceutical company. His role at Pfizer allows him to collaborate with some of the brightest minds in the industry, contributing to groundbreaking research and development.

Collaborations

Pelc has worked alongside talented colleagues such as Tanisha D Blake and Bruce C Hamper. Their combined expertise fosters an environment of innovation and creativity, leading to advancements in pharmaceutical research.

Conclusion

Matthew J Pelc's contributions to the field of pharmaceuticals through his patents and collaborations highlight his commitment to improving healthcare solutions. His work continues to pave the way for new treatments that can significantly benefit patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…